Interleukin 12: still a promising candidate for tumor immunotherapy?
Lasek W, Zagożdżon R, Jakobisiak M. · 2014
Read Interleukin 12: still a promising candidate for tumor immunotherapy? by Lasek W, Zagożdżon R, Jakobisiak M. (2014) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3994286.txt.
Description
Witold Lasek, Radosław Zagożdżon, and Marek Jakobisiak weigh an immune signal called interleukin 12 as a cancer treatment, in Cancer Immunology, Immunotherapy in 2014. The signal links the innate and adaptive arms of the immune system. It wakes natural killer cells and killer T cells, and drives output of a second signal that fights tumours.
In animal tests the effects looked strong. Early human trials, though, gave weak gains and harsh side effects, which cooled hope for the drug. The review covers a fresh round of approaches now in trials. These use the signal as a boost for cancer vaccines, deliver its gene by shots into or near tumours, or fuse it to antibodies that home to tumours. Whether this second wave helps a select group of patients should soon become clear.
Catalog record
| CREATOR | Lasek W, Zagożdżon R, Jakobisiak M. |
|---|---|
| YEAR | 2014 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 90 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |